Nexavar
Developed to address carcinoma growth to alleviate tumour progression.
- Category
- Oncology Support
- Active ingredient
- Sorafenib
- Supply
- Rx
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 200mg
Nexavar details
- Therapeutic class
- Kinase inhibitor
- Pharmacological class
- Antineoplastic agent
- Contraindications
- hypersensitivity to sorafenib; pregnancy
- Minor side effects
- diarrhoea; fatigue; alopecia; rash; hand-foot syndrome
- Moderate side effects
- hypertension; weight loss; anorexia
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Patient summary
- Developed to address carcinoma growth to alleviate tumour progression.
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Bayer
- Onset Time
- Variable
- Duration
- Ongoing
- Storage instructions
- Store below 25°C.
- Drug interactions
- Warfarin; Docetaxel
- Age restrictions
- Not for children.
- Pregnancy and breastfeeding
- Pregnancy: Use is contraindicated. Breastfeeding: Discontinue during treatment.
Precautions and warnings
monitor skin reactions; check blood pressure regularly; discontinue if cardiac ischaemia occurs
Serious side effects
cardiac ischaemia, requires immediate medical attention; haemorrhage, requires immediate medical attention; gastrointestinal perforation, requires immediate medical attention
Mechanism of action
Sorafenib is a multikinase inhibitor that suppresses tumour cell proliferation and angiogenesis by inhibiting intracellular and cell surface kinases.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Nexavar
Nexavar is a medication containing sorafenib, used in the treatment of hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma. It is manufactured by Bayer and supplied as 200mg tablets. This therapy works by supporting the management of these specific cancer conditions.
Nexavar availability in Asia
Nexavar is registered across 14 markets, including Hong Kong, Thailand and Malaysia, with availability also in the Philippines, Indonesia and Taiwan. Generic sorafenib, much of it produced in India, is far more affordable than the original brand, offering broader access for both local residents and expats who may be far from well-stocked medical facilities. Such treatments are best utilised under the ongoing supervision of a doctor to ensure appropriate care for complex conditions.